206 related articles for article (PubMed ID: 25689017)
1. Cutting the Gordian helix--regulating genomic testing in the era of precision medicine.
Lander ES
N Engl J Med; 2015 Mar; 372(13):1185-6. PubMed ID: 25689017
[No Abstract] [Full Text] [Related]
2. Genetic testing and FDA regulation: overregulation threatens the emergence of genomic medicine.
Evans JP; Watson MS
JAMA; 2015 Feb; 313(7):669-70. PubMed ID: 25560537
[No Abstract] [Full Text] [Related]
3. The FDA and genomic tests--getting regulation right.
Evans BJ; Burke W; Jarvik GP
N Engl J Med; 2015 Jun; 372(23):2258-64. PubMed ID: 26014592
[No Abstract] [Full Text] [Related]
4. Science and regulation. Regulating direct-to-consumer personal genome testing.
McGuire AL; Evans BJ; Caulfield T; Burke W
Science; 2010 Oct; 330(6001):181-2. PubMed ID: 20929761
[No Abstract] [Full Text] [Related]
5. 23andMe and the FDA.
Annas GJ; Elias S
N Engl J Med; 2014 Mar; 370(11):985-8. PubMed ID: 24520936
[No Abstract] [Full Text] [Related]
6. A warning that must not be ignored.
Hudson K
New Sci; 2003 May; 178(2393):5. PubMed ID: 14686409
[No Abstract] [Full Text] [Related]
7. Separating predictive genetic testing from snake oil: regulation, liabilities, and lost opportunities.
Malinowski MJ
Jurimetrics; 2000; 41(1):23-52. PubMed ID: 15744897
[TBL] [Abstract][Full Text] [Related]
8. Standard issue.
Nature; 2010 Aug; 466(7308):797. PubMed ID: 20703263
[No Abstract] [Full Text] [Related]
9. US urged to monitor some genetic tests.
Wadman M
Nature; 1997 Feb; 385(6616):477. PubMed ID: 9020348
[No Abstract] [Full Text] [Related]
10. Ensuring quality in genomic medicine: amid the rise in complex laboratory-developed tests, regulatory officials are seeking the right balance on quality assurance.
Nelson B
Cancer Cytopathol; 2014 Dec; 122(12):855-6. PubMed ID: 25510938
[No Abstract] [Full Text] [Related]
11. In search of a coherent framework: options for FDA oversight of genetic tests.
Javitt GH
Food Drug Law J; 2007; 62(4):617-52. PubMed ID: 18557224
[No Abstract] [Full Text] [Related]
12. Innovation, risk, and patient empowerment: the FDA-mandated withdrawal of 23andMe's Personal Genome Service.
Downing NS; Ross JS
JAMA; 2014 Feb; 311(8):793-4. PubMed ID: 24474248
[No Abstract] [Full Text] [Related]
13. Regulation: The FDA is overcautious on consumer genomics.
Green RC; Farahany NA
Nature; 2014 Jan; 505(7483):286-7. PubMed ID: 24436984
[No Abstract] [Full Text] [Related]
14. A public health perspective on the control of predictive screening for breast cancer.
Cunningham GC
Health Matrix Clevel; 1997; 7(1):31-48. PubMed ID: 10167177
[No Abstract] [Full Text] [Related]
15. FDA moves to regulate thousands of diagnostic tests.
Caffrey MK
Am J Manag Care; 2014 Aug; 20(11 Spec No.):E12. PubMed ID: 25618155
[No Abstract] [Full Text] [Related]
16. The need for increased oversight of genetic testing: a detailed look at the genetic testing process.
Bonnin DC
Houst J Health Law Policy; 2003; 4(1):149-80. PubMed ID: 16596751
[No Abstract] [Full Text] [Related]
17. Are genetic tests adequately regulated?
Holtzman NA
Science; 1999 Oct; 286(5439):409. PubMed ID: 10577197
[No Abstract] [Full Text] [Related]
18. Impact of microarray data quality on genomic data submissions to the FDA.
Frueh FW
Nat Biotechnol; 2006 Sep; 24(9):1105-7. PubMed ID: 16964222
[No Abstract] [Full Text] [Related]
19. Which way for genetic-test regulation? Leave test interpretation to specialists.
Beaudet AL
Nature; 2010 Aug; 466(7308):816-7. PubMed ID: 20703287
[No Abstract] [Full Text] [Related]
20. Direct-to-consumer personalized genomic testing.
Bloss CS; Darst BF; Topol EJ; Schork NJ
Hum Mol Genet; 2011 Oct; 20(R2):R132-41. PubMed ID: 21828075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
